Partnership with Bio-venture
Collaboration started on November 23, 2021
“We are so happy to be partnering with Astellas, a world leader in developing gene therapies. Dyno and Astellas each bring unique strengths to this collaboration, together enabling more rapid creation of new therapies for patients with great unmet need. This partnership demonstrates the flexibility of Dyno’s platform to precisely design the delivery properties of gene therapy vectors towards multi-organ and disease-specific profiles, applying the scientific insights we are rapidly learning across all our partnered and internal vector engineering programs using CapsidMap.”
Eric D. Kelsic, Ph.D.
Dyno’s CEO and Co-founder
Collaboration started on July 30, 2021
“We are excited and honored to collaborate with Astellas. We share with Astellas both their passion for mitochondrial science and their commitment to patients in need of new therapies. As Minovia continues the development of Mitochondrial Augmentation Therapy, we believe this partnership is critical to accelerate the development of off-the-shelf, allogeneic cell therapy programs for the many patients living with mitochondrial diseases caused by mitochondrial dysfunction.”
Natalie Yivgi-Ohana, Ph.D.
Minovia’s CEO and Co-founder
*Quote from the press release:
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
Partnership with Academia
Licensing Agreement started on September 2, 2019
“Artificial adjuvant vector cell (aAVC) is a new type of unique cell therapy formulation with a different mechanism of action from previous immunotherapy agents. In September 2019, we have provided our aAVC technology to Astellas and advanced the technology to the clinical development stage. As a medical researcher, I have been aiming at delivering basic science to clinical research. I think this project is another bridge from academia to industry. We can also say that it has opened the new door in the development of immune cell-based agents in industry-academia collaboration originating in Japan.”
Shinichiro Fujii, M.D., Ph.D.
Deputy Program Director, RIKEN Program for Drug Discovery and
Medical Technology Platforms, RIKEN Cluster for Science,
Technology and Innovation Hub, and Team Leader, Laboratory for
Immunology, RIKEN Center for Integrative Medical Sciences
*Quote from the press release:
RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology
Voice from a Company That Joined Astellas
Acquired on December 26, 2019
“Astellas has a powerful vision to develop off-the-shelf cellular therapies to greatly improve access and deliver to cancer patients the best possible outcomes. Xyphos is truly a part of this shared vision – something the team is reminded of daily as we work with other research divisions throughout the organization to solve pieces of this very complex puzzle and as the organization continuously seeks opportunities to engage in external partnerships to accelerate the realization of this vision. The dedication of the leadership teams, the drive of the scientists, and the quality of the support provided by all the groups that nurture a therapy’s journey from early research to patient outcomes has been inspirational. Xyphos is privileged to be part of Astellas’ Primary Focus Immuno-Oncology vision.”